PRDS 0.00 Pardes Biosciences, Inc.
| Range: | 0.75-3.67 | Vol Avg: | 509687 | Last Div: | 0 | Changes: | 0.02 |
| Beta: | 0.42 | Cap: | 0.14B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Dec 27 2021 | Empoloyees: | 57 | ||
| CUSIP: | 69945Q105 | CIK: | 0001822711 | ISIN: | US69945Q1058 | Country: | US |
| CEO: | Mr. Thomas G. Wiggans | Website: | https://www.pardesbio.com | ||||
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow